Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Nalinikanth Gollagunta...

    Nalinikanth Gollagunta appointed as President and CEO of GE Healthcare India, South Asia

    Written by Ruby Khatun Khatun Published On 2017-08-03T09:30:48+05:30  |  Updated On 16 Aug 2021 3:25 PM IST

    Bangalore: GE Healthcare announced the appointment of Nalinikanth (Nal) Gollagunta as President and CEO, GE Healthcare India and South Asia and Managing Director, Wipro GE Healthcare, effective on 2nd August, 2017.


    Nal joins GE Healthcare from CISCO where he was the Country Head and Managing Director, Enterprise Sales - India and SAARC region. He succeeds Milan Rao who has decided to pursue opportunities outside of GE, and will be joining Wipro Limited after four successful years with the company. NAL will report to Azim Premji, Chairman, Wipro Ltd. and Terri Bresenham, President and CEO, GE Healthcare, SHS.


    "Wipro and GE Healthcare enjoy one of the most successful and enduring partnership lasting over 28 years and has made a positive impact on India's healthcare industry. I am confident Nal will further strengthen this relationship and give an added impetus to our mission to build a healthy India and a healthier world," said Azim Premji, Chairman, Wipro Ltd.


    Nal will be responsible for building on Wipro GE's expansion plans, delivering on commercial outcomes, strategic growth objectives, and driving partnerships in the region. He will continue to strengthen the company's 'In India, for India and the world' proposition of innovating disruptive technology and business solutions to enhance access to high-quality, affordable healthcare solutions.


    Terri Bresenham, President and CEO, GE Healthcare SHS said, "Nal is a strong commercial, strategy and technology leader with deep expertise of the rapidly evolving digital space. His understanding of enterprise business solutions and technology will enable development of disruptive technologies and business models which will help improve outcomes for healthcare systems and patients in South Asia. His leadership and skills will be a key asset as we continue to innovate and grow our business in the region, and pursue our mission of a Healthy India and a Healthier world."


    "I am delighted to join Wipro GE Healthcare at an exciting time in the company's growth and look forward to leveraging my experience as a technologist and enterprise leader to help fundamentally transform the healthcare space in India. The potential that lies ahead for Wipro GE Healthcare in India and for SHS globally is enormous, and the opportunity to contribute to this next chapter is deeply humbling and incredibly exhilarating," said Nal.


    Nal has over 17 years of senior management and leadership experience with stints in Texas Instruments, McKinsey and CISCO across India, Singapore and USA. He holds an Electrical Engineering degree from IIT - Madras/Chennai; a Master of Science from the Pennsylvania State University and a MBA from Cornell University.

    appointmentappointsAzim PremjiGE HealthcareIndiaManaging directorNalinikanth GollaguntaPresidentSouth AsiaTerri BresenhamWipro GE HealthcareWipro Limited
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok